Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Transferability of indirect cost of chronic disease: a systematic review and meta-analysis.

Zhao FL, Xie F, Hu H, Li SC.

Pharmacoeconomics. 2013 Jun;31(6):501-8. doi: 10.1007/s40273-013-0053-6. Review.

PMID:
23620212
2.

Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples.

Gao L, Hu H, Zhao FL, Li SC.

PLoS One. 2016 Jan 27;11(1):e0147169. doi: 10.1371/journal.pone.0147169. eCollection 2016. Review.

3.

[Cost of lost productivity in pharmacoeconomics analysis. Part I. A systematic review of the literature].

Wrona W, Hermanowski T, Golicki D, Jakubczyk M, Macioch T, Goszczyńska K, Wójcik R.

Przegl Epidemiol. 2011;65(1):147-52. Review. Polish.

PMID:
21735852
5.

Modeling the lifetime costs of rheumatoid arthritis.

Gabriel SE, Crowson CS, Luthra HS, Wagner JL, O'Fallon WM.

J Rheumatol. 1999 Jun;26(6):1269-74.

PMID:
10381041
6.

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.

Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E.

Pharmacoeconomics. 2005;23(4):377-93.

PMID:
15853437
7.

The Economic Costs of Type 2 Diabetes: A Global Systematic Review.

Seuring T, Archangelidi O, Suhrcke M.

Pharmacoeconomics. 2015 Aug;33(8):811-31. doi: 10.1007/s40273-015-0268-9. Review.

8.

Cost of disorders of the brain in Europe 2010.

Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jönsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen HC, Stovner LJ, Vallat JM, Van den Bergh P, van Os J, Vos P, Xu W, Wittchen HU, Jönsson B, Olesen J; CDBE2010Study Group.

Eur Neuropsychopharmacol. 2011 Oct;21(10):718-79. doi: 10.1016/j.euroneuro.2011.08.008. Epub 2011 Sep 15. Erratum in: Eur Neuropsychopharmacol. 2012 Mar;22(3):237-8. den Bergh, Peter Van [corrected to Van den Bergh, Peter].

PMID:
21924589
9.

The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program.

Grøn KL, Ornbjerg LM, Hetland ML, Aslam F, Khan NA, Jacobs JW, Henrohn D, Rasker JJ, Kauppi MJ, Lang HC, Mota LM, Aggarwal A, Yamanaka H, Badsha H, Gossec L, Cutolo M, Ferraccioli G, Gremese E, Bong Lee E, Inanc N, Direskeneli H, Taylor P, Huisman M, Alten R, Pohl C, Oyoo O, Stropuviene S, Drosos AA, Kerzberg E, Ancuta C, Mofti A, Bergman M, Detert J, Selim ZI, Abda EA, Rexhepi B, Sokka T.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6):869-77. Epub 2014 Oct 20.

PMID:
25327997
10.

Cost-of-illness studies : a review of current methods.

Akobundu E, Ju J, Blatt L, Mullins CD.

Pharmacoeconomics. 2006;24(9):869-90. Review.

PMID:
16942122
11.

Generalisability in economic evaluation studies in healthcare: a review and case studies.

Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, Davies LM, Eastwood A.

Health Technol Assess. 2004 Dec;8(49):iii-iv, 1-192. Review.

12.

Economic burden of rheumatoid arthritis: a systematic review.

Cooper NJ.

Rheumatology (Oxford). 2000 Jan;39(1):28-33. Review.

PMID:
10662870
13.

Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database.

Sokka T, Kautiainen H, Pincus T, Toloza S, da Rocha Castelar Pinheiro G, Lazovskis J, Hetland ML, Peets T, Immonen K, Maillefert JF, Drosos AA, Alten R, Pohl C, Rojkovich B, Bresnihan B, Minnock P, Cazzato M, Bombardieri S, Rexhepi S, Rexhepi M, Andersone D, Stropuviene S, Huisman M, Sierakowski S, Karateev D, Skakic V, Naranjo A, Baecklund E, Henrohn D, Gogus F, Badsha H, Mofti A, Taylor P, McClinton C, Yazici Y.

Ann Rheum Dis. 2009 Nov;68(11):1666-72. doi: 10.1136/ard.2009.109983. Epub 2009 Jul 30.

14.

A comparison of methods to handle skew distributed cost variables in the analysis of the resource consumption in schizophrenia treatment.

Kilian R, Matschinger H, Löeffler W, Roick C, Angermeyer MC.

J Ment Health Policy Econ. 2002 Mar;5(1):21-31.

PMID:
12529567
15.

Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls.

Gabriel SE, Crowson CS, Campion ME, O'Fallon WM.

J Rheumatol. 1997 Jan;24(1):43-8.

PMID:
9002009
16.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
17.

The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.

Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, Casciano R, Ciuryla V.

Clin Ther. 2008 Feb;30(2):341-57. doi: 10.1016/j.clinthera.2008.02.003. Review.

PMID:
18343273
18.

Indirect health costs in ulcerative colitis and Crohn's disease: a systematic review and meta-analysis.

Kawalec P, Malinowski KP.

Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):253-66. doi: 10.1586/14737167.2015.1011130. Epub 2015 Feb 6. Review.

PMID:
25656310
19.

Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).

Brettschneider C, Lühmann D, Raspe H.

GMS Health Technol Assess. 2011 Feb 2;7:Doc01. doi: 10.3205/hta000092.

20.

Economic costs of adult obesity: a review of recent European studies with a focus on subgroup-specific costs.

von Lengerke T, Krauth C.

Maturitas. 2011 Jul;69(3):220-9. doi: 10.1016/j.maturitas.2011.04.005. Epub 2011 May 18. Review.

PMID:
21592692

Supplemental Content

Support Center